Daniel Haders, the CEO of Model Medicines, will be participating as a panelist, bringing his expertise to the conference. The event covers a wide range of drug discovery topics and offers excellent networking opportunities. Daniel will delve into the theme "Advancing Hit Discovery for Complex and Emerging Targets," aligning seamlessly with Model Medicines' groundbreaking work.